AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03810105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg IV monthly
Study NCT01850758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx SD
Description: stem cell treatment
Study NCT01850758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: exercise therapy control
Study NCT01607684 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Marker Imaging (MMI) with Magma 3D system
Description: Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
Study NCT04628325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
Study NCT04628325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
Study NCT00936780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinnium-Core™ Paclitaxel eluting Coronary Stent
Description: Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
Study NCT02668393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Study NCT02668393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: Low Dose
Study NCT02668393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: Medium dose
Study NCT02668393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: High dose
Study NCT02668393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: Continuous high dose
Study NCT04618107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide awake surgery
Description: Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
Study NCT04618107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
Study NCT01933685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
Study NCT01933685 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E Placebo
Description: 1 mL per injection
Study NCT03207061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D Ultrasound
Description: A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
Study NCT03695367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
Study NCT03695367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation.
Study NCT03695367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product.
Study NCT03695367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen, 600 mg.
Study NCT03695367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen, 1 g.
Study NCT03695367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Intraoperative IV ketorolac.
Study NCT00644982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
Study NCT00644982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine XR
Description: Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
Study NCT01809743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson central -central
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Study NCT01809743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson peripheral - peripheral
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Study NCT01809743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson central - peripheral
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Study NCT01809743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson peripheral - central
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Study NCT01809743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
Study NCT03453138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Protector
Description: LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
Study NCT03453138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation
Description: tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
Study NCT04695808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: Yoga practice will be done two days a week for 10 weeks.
Study NCT02344524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal drainage
Description: Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
Study NCT02344524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intercostal drainage
Description: Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
Study NCT03519711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 will be administered per dose and schedule specified in arm description.
Study NCT00986037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-308
Description: Single IV doses
Study NCT00986037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-308
Description: Multiple SC doses x 3
Study NCT00986037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single IV dose
Study NCT00986037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple SC doses x 3
Study NCT04469764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT04469764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT04469764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT03869697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: 5 mg or 20 mg lyophilized powder in a single-use glass vial
Study NCT01638871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainCOACH
Description: The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
Study NCT00176267 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50 cGy on days 1, 2, 8, 15, 22, 23, 29 \& 36 of chemotherapy
Study NCT00176267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
Study NCT00176267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 6 on Days 1 \& 22
Study NCT04664127 — intervention group
Intervention type: DRUG
Intervention: Kagocel+Valacyclovir
Description: Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment \[Valacyclovir + Kagocel ° \] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). \* Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months
Study NCT04664127 — intervention group
Intervention type: DRUG
Intervention: Valacyclovir
Description: Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment \[Valacyclovir\] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)\*.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months.
Study NCT00607373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
Study NCT00607373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
Study NCT03722004 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV1
Description: Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.
Study NCT03722004 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV
Description: Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.
Study NCT03722004 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
Study NCT01809119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial nephrectomy
Study NCT01809119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial nephrectomy
Study NCT01810536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hi-flow nasal cannula
Description: Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
Study NCT01810536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Study NCT03881215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma
Study NCT03881215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-uterine balloon
Description: intra-uterine balloon
Study NCT03881215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-uterine balloon
Description: intra-uterine balloon
Study NCT04449263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: Subjects will be randomized to wear Lens A (test) for 2 weeks.
Study NCT04449263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens A
Description: Subjects will be randomized to wear Lens A (test) for 2 weeks.
Study NCT04449263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: Subjects will be randomized to wear Lens B (control) for 2 weeks.
Study NCT04449263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens B
Description: Subjects will be randomized to wear Lens B (control) for 2 weeks.
Study NCT04449263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Lenses
Description: All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
Study NCT04449263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual Lenses
Description: All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
Study NCT03956446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
Study NCT03956446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic therapy
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study NCT03956446 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Symptomatic therapy
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study NCT03956446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study NCT03956446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study NCT04388254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simufilam 100 mg oral tablet
Description: Simufilam 100 mg oral tablet for b.i.d. administration
Study NCT04388254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam 100 mg oral tablet
Description: Simufilam 100 mg oral tablet for b.i.d. administration
Study NCT04388254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablets
Study NCT00857688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismu-Jet
Description: Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
Study NCT00857688 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
Study NCT02181244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg, one a day, for breakfast
Description: One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
Study NCT02181244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal, one cup a day
Description: Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
Study NCT01212341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK cells
Study NCT00583076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
Study NCT01234389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electrochemical H. pylori detection method
Description: Determination of H. pylori infection.
Study NCT01234389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IHC
Description: Determination of H. pylori infection.
Study NCT01234389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: C13-urea breath test
Description: Determination of H. pylori infection.
Study NCT01234389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HUT
Description: Determination of H. pylori infection.
Study NCT02596932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Protocol for intrapartum glucose management
Description: Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or \< 60mg/dL
Study NCT02596932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Protocol for intrapartum glucose management
Description: Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or \< 60 mg/dL
Study NCT02602210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
Study NCT02602210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCL 0.9%
Description: IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
Study NCT01607255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo carmine
Description: 0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
Study NCT01607255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water (exchange) method
Description: Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
Study NCT01607255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water (exchange) plus dye method
Description: Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
Study NCT01607255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air method
Description: The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.